Reaction Details |
| Report a problem with these data |
Target | Early activation antigen CD69 |
---|
Ligand | BDBM50583942 |
---|
Substrate/Competitor | n/a |
---|
Meas. Tech. | ChEMBL_2158455 (CHEMBL5043205) |
---|
IC50 | 40±n/a nM |
---|
Citation | Hopkins, BT; Bame, E; Bajrami, B; Black, C; Bohnert, T; Boiselle, C; Burdette, D; Burns, JC; Delva, L; Donaldson, D; Grater, R; Gu, C; Hoemberger, M; Johnson, J; Kapadnis, S; King, K; Lulla, M; Ma, B; Marx, I; Magee, T; Meissner, R; Metrick, CM; Mingueneau, M; Murugan, P; Otipoby, KL; Polack, E; Poreci, U; Prince, R; Roach, AM; Rowbottom, C; Santoro, JC; Schroeder, P; Tang, H; Tien, E; Zhang, F; Lyssikatos, J Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple Sclerosis. J Med Chem65:1206-1224 (2022) [PubMed] Article |
---|
More Info.: | Get all data from this article, Assay Method |
---|
|
Early activation antigen CD69 |
---|
Name: | Early activation antigen CD69 |
Synonyms: | AIM | Activation inducer molecule | BL-AC/P26 | C-type lectin domain family 2 member C | CD69 | CD69_HUMAN | CD_antigen=CD69 | CLEC2C | EA1 | Early T-cell activation antigen p60 | Early activation antigen CD69 | GP32/28 | Leukocyte surface antigen Leu-23 | MLR-3 |
Type: | PROTEIN |
Mol. Mass.: | 22559.65 |
Organism: | Homo sapiens |
Description: | ChEMBL_109097 |
Residue: | 199 |
Sequence: | MSSENCFVAENSSLHPESGQENDATSPHFSTRHEGSFQVPVLCAVMNVVFITILIIALIA
LSVGQYNCPGQYTFSMPSDSHVSSCSEDWVGYQRKCYFISTVKRSWTSAQNACSEHGATL
AVIDSEKDMNFLKRYAGREEHWVGLKKEPGHPWKWSNGKEFNNWFNVTGSDKCVFLKNTE
VSSMECEKNLYWICNKPYK
|
|
|
BDBM50583942 |
---|
n/a |
---|
Name | BDBM50583942 |
Synonyms: | CHEMBL5088454 |
Type | Small organic molecule |
Emp. Form. | C28H37N7O |
Mol. Mass. | 487.6397 |
SMILES | Cn1cc(Nc2nccc(n2)-c2ccc3C(CCCCc3c2)NC(=O)N2CC[C@H](C2)C(C)(C)C)cn1 |r| |
Structure |
|